

SUPPLEMENT INFORMATION

Supplemental Tables

Table S1. Demographic and clinical parameters of SLE patients and healthy cohorts.

Patient characteristic	Plasma			Urine		
	SLE (n=115)	HC (n=82)	p-value	SLE (n=128)	HC (n=82)	p-value
Demographical features						
Ethnics (Chinese Han/Hui)	89/26	68/14	0.341	88/40	60/22	0.493
Age (mean±SD)(range, year old)	40.32±12.11	34.56±9.88	0.412	42.12±11.35	33.78±10.12	0.434
Gender (male/female)	35/80	22/60	0.582	47/81	30/52	0.984
Disease features						
Disease duration (mean±SD)	10.56±4.12			11.72±4.48		
SLEDAI score (range)	10.66±5.67			12.78±6.12		
Clinical manifestations						
Renal disorder (n,%)	55(47.82%)			70(54.69%)		
Musculoskeletal (n,%)	50(43.48%)			55(42.97%)		
Haematological (n,%)	111(96.50%)			119(92.97%)		
Neuropsychiatric (n,%)	27(23.48%)			29(22.66%)		
Serositis (n,%)	27(23.48%)			21(16.41%)		
cutaneous (n,%)	76 (70.40%)			85 (66.41%)		
Treatment						
Prednisone (n,%)	90(78.26%)			97(75.78%)		
Azathioprine (n,%)	68(59.13%)			72(56.25%)		
Antimalarial (n,%)	64(55.65%)			64(50.79%)		
Cydophosphamide (n,%)	14(12.17%)			21(16.41%)		
Methotrexate (n,%)	21(18.26%)			25(19.53%)		
Laboratory						
ESR (mm h ⁻¹ , mean±SD)	32±2.11	27±3.14	0.157	34±3.22	28±2.35	0.146
Anti-dsDNA (IU/ML, mean±SD)	214.45±103.76	90.30±70.17	0.000	235.17±98.21	87.23±67.95	0.000
C3 (µg/mL, mean±SD)	0.48±0.18	0.60±0.19	0.000	0.47±0.21	0.47±0.13	0.112
C4 (µg/mL, mean±SD)	0.054±0.02	0.057±0.02	0.146	0.055±0.03	0.056±0.02	0.135
Proteinuria (>500mg/day, n, %)	50(39.7%)			61(48.4%)		

C3: Complement C3; C4: Complement C4; dsDNA: double-stranded DNA; ESR: erythrocyte sedimentation rate; SLE: Systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index

Table S2. The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). Reprinted by permission from the University of Pennsylvania, copyright 2009.

Erythema	Scale/ Hypertrophy	Anatomical Location		Scarring/ Atrophy/ Panniculitis	Dyspigmentation
0=absent 1=pink faint erythema 2=red 3=dark red; Purple/violaceous/cru sted/hemorrhagic	0=absent 1=scale 2=verrucous/ hypertrophic			0=absent 1=scarring 2=severely atrophic scarring or panniculitis	0=absent 1=dyspigmentation
		Scalp			See below
		Ears			
		Nose(incl. malar area)			
		Rest of face			
		V-area neck(frontal)			
		Post. Neck&/or shoulder			
		Chest			
		Abdomen			
		Back, buttocks			
		Arms			
		Hands			
		Legs			
		Feet			
Mucous membrane lesions (examine if patient confirms involvement) 0=absent 1=lesion or ulceration				Dyspigmentation usually lasts less than 12 months (score above remains) or at least 12 months (score is double)	
Divide the scalp into four quadrants as shown. The dividing line between right and left is the midline. The dividing line between frontal and occipital is the line connecting the highest points of the ear lobe.					
Alopecia (clinically not obviously scarred) 0=absent 1=diffuse; noninflammatory 2=focal or patchy in one quadrant 3=focal or patchy in one quadrant		Total Activity Score	Total Damage Score	Scarring of the scalp (judged clinically) 0=absent 1=in one quadrant 2=two quadrants 3= three quadrants 4=affects the whole skull	